The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Over 8.8?million Indians aged 60 and above currently live with dementia,
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Subscribe To Our Newsletter & Stay Updated
